Comparison

Amycretin vs. VK2735

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Amycretin	VK2735
Germany	Unapproved	Unapproved
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Amycretin and VK2735?: Amycretin is classified as "Metabolic", while VK2735 is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or VK2735?: The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and VK2735 in Germany and the United States?: Germany: Amycretin — Unapproved, VK2735 — Unapproved. United States: Amycretin — Unapproved, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

VK2735

Germany

Unapproved

United States

Unapproved

Frequently asked questions

What is the difference between Amycretin and VK2735?

Amycretin is classified as "Metabolic", while VK2735 is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or VK2735?

The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and VK2735 in Germany and the United States?

Germany: Amycretin — Unapproved, VK2735 — Unapproved. United States: Amycretin — Unapproved, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.